Skip to main content

Clinical trial COBRIM

GO28141 A phase III, double-blind, placebo-controlled study of Vemurafenib versus Vemurafenib plus GDC-0973 in previously untreated BRAFV600-mutation positive patients with unresectable locally Advanced or metastatic melanoma

Organ Skin
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Roche
EudraCT Identifier 2012-00300-811
Inclusion criteria BRAF V600 mutation
Last update